Progress in diagnosis and treatment of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia

VernacularTitle:儿童急性淋巴细胞白血病合并门冬酰胺酶相关性胰腺炎的诊治进展
Author: Yao XIAO ¹ ; Jie YU
Author Information

1. 重庆医科大学附属儿童医院血液肿瘤科　400014
Keywords: Asparaginase; Asparaginase-associated pancreatitis; Acute lymphoblastic leukemia; Children
From: Chinese Pediatric Emergency Medicine 2022;29(8):584-588
CountryChina
Language:Chinese
Abstract: There is growing evidence of significant clinical and biological benefits of asparaginase (ASP) as a key agent in multidrug combination chemotherapy for pediatric acute lymphoblastic leukemia (ALL), and the drug will continue to be used at higher total doses in intermediate- and high-risk patients.However, high doses of ASP can lead to treatment-related toxicities.Among them, asparaginase-associated pancreatitis (AAP), which is a life-threatening treatment-limiting side effect of chemotherapy, will lead to interruption or complete discontinuation of ASP at grade 3 or 4 in adverse event evaluations, while interruption or discontinuation of ASP may lead to relapse in patients with ALL with an increased risk of remission failure in the case of relapse.Rapid identification and management of AAP will help ensure that patients derive maximum benefit from ASP therapy.This review summarized the diagnosis and management of AAP, possible risk factors, and prudent re-exposure to ASP after the first episode of AAP.